BioCentury
ARTICLE | Clinical News

Liposomal Grb-2 regulatory update

May 4, 2015 7:00 AM UTC

FDA granted Orphan Drug designation to Liposomal Grb-2 from Bio-Path to treat acute myelogenous leukemia (AML). The liposomal antisense inhibitor of growth factor receptor-bound protein 2 (GRB2) expr...